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Abstract
Background: Patient reported outcomes (PROs) are increasingly assessed in clinical trials, and guidelines are available to
inform the design and reporting of such trials. However, researchers involved in PRO data collection report that specific
guidance on ‘in-trial’ activity (recruitment, data collection and data inputting) and the management of ‘concerning’ PRO
data (i.e., data which raises concern for the well-being of the trial participant) appears to be lacking. The purpose of this
review was to determine the extent and nature of published guidelines addressing these areas.
Methods and Findings: Systematic review of 1,362 articles identified 18 eligible papers containing ‘in-trial’ guidelines. Two
independent authors undertook a qualitative content analysis of the selected papers. Guidelines presented in each of the
articles were coded according to an a priori defined coding frame, which demonstrated reliability (pooled Kappa 0.86–0.97),
and validity (,2% residual category coding). The majority of guidelines present were concerned with ‘pre-trial’ activities
(72%), for example, outcome measure selection and study design issues, or ‘post-trial’ activities (16%) such as data analysis,
reporting and interpretation. ‘In-trial’ guidelines represented 9.2% of all guidance across the papers reviewed, with content
primarily focused on compliance, quality control, proxy assessment and reporting of data collection. There were no
guidelines surrounding the management of concerning PRO data.
Conclusions: The findings highlight there are minimal in-trial guidelines in publication regarding PRO data collection and
management in clinical trials. No guidance appears to exist for researchers involved with the handling of concerning PRO
data. Guidelines are needed, which support researchers to manage all PRO data appropriately and which facilitate unbiased
data collection.
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Introduction
Patient reported outcomes (PROs) such as health-related quality
of life (HRQL) are increasingly assessed in clinical trials.[1–3]
PROs provide researchers, clinicians and patients with important
information regarding the effect of a disease and its treatment: on
symptoms (for example, pain or fatigue) and on HRQL or
satisfaction with care.[4] In general, patients participating in a trial
do not directly benefit from completing a PRO questionnaire. This
approach is adopted to ensure trial participants are not tempted to
tailor their answers in order to influence the treatment they receive
within a study, which is a potential source of bias.[5,6] PRO
results are therefore used to inform the care of future patients[6],
who, with their clinicians, may use PRO data to inform significant
health-care decisions. For example, between interventions offering
similar survival or progression-free survival rates, or those that
have differing trade-offs between therapeutic benefit and undesir-
able side-effects.[4] Thus, it is crucial that PROs are administered
and processed in an un-biased way.
In order to ensure high quality PRO trial data, consistent and
rigorous standardised data collection methods should be used
throughout a trial.[7] The use of standardised methods should
serve to minimise errors, measurement variability, missing data
and systematic bias, thus contributing to the validity of trial
results.[8] Local site staff require access to ‘in-trial’ (i.e. recruit-
ment, data collection and data inputting, see Box S1) guidelines
that clearly outline the standardised methods in-use, so that all
study personnel may fully incorporate them into practice. Such
guidelines should be contained within the trial protocol, supported
by standard operating procedures (SOPs) where appropriate.
It is of concern, therefore, that anecdotal evidence - obtained
during national quality of life training days run by the MRC
Midland Hub for Trials Methodology in the UK - suggests that in-
trial PRO guidelines are not routinely included within trial
documentation and that, as a result, unstandardised PRO data
collection may be common. Researchers also report feeling
particularly uncomfortable that they receive no specific guidance
on how to manage ‘concerning’ PRO data, i.e. data that might
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raise concern for the wellbeing of the trial participant in some way.
Staff encountering such data - commonly represented by markedly
low HRQL scores, or unexpected unprompted additional
information recorded on the back of questionnaires - were
therefore unsure where their responsibility should lie, or whether
they should be viewing this information in the first place. In this
situation, some described experiencing a ‘dual-role’ tension
between their concurrent responsibilities as a clinician and
researcher: the duty to act upon the information to benefit the
patient verses that of protecting trial integrity by not intervening.
In some instances, reports indicated that off-protocol concomitant
interventions had been administered, some of which may not have
been captured by standard trial reporting mechanisms. Such
interventions have the potential to bias trial results. These
anecdotal reports have since been supported by a recently
completed qualitative study, in which we used semi-structured
interviews to explore the experiences of 26 research nurses,
research facilitators, trial coordinators and data managers across
three NHS sites and two clinical trials units in the UK[9] (under
review). This study confirmed a potential for bias associated with
concerning PRO data, during both postal or clinic-based and self-
reported or researcher/research nurse-assisted data collection.
These reports suggest a lack of in-trial PRO guidance, with a
subsequent absence of systematic monitoring of potentially
concerning PRO data and a resulting risk of bias. It is uncertain,
however, whether they also reflect a deficiency in the published
literature in this area. There are recent publications concerning
the design of trials with a PRO outcome[7,10] and, with the
development of the CONSORT PRO extension[11], there is now
guidance to improve PRO reporting: it remains unclear if the
literature provides adequate coverage of in-trial issues.
The purpose of this study was to systematically review the
current published in-trial PRO guidance, as no review of this kind
had been previously undertaken. The objectives for our review
were:
N To investigate the extent and content of the current in-trial
PRO guidelines in publication.
N To determine if these guidelines adequately address questions
raised by researchers involved in PRO data collection,
surrounding the management of concerning PRO data.
Methods
Search strategy
The MEDLINE (Ovid), EMBASE, AMED and CINHAL+
databases were searched from inception to March 2012 (electronic
search strategies are presented in full in Appendix S1). We also
searched; the US Food and Drug Administration[12], European
Medicines Agency[13], General Medical Council[14], Medical
Research Council[15] and Royal College of Nursing[16] websites;
PROQUEST (Thesis repository); Google; and made use of expert
communication in an attempt to find additional potentially eligible
papers not returned during the electronic database search.
Records were first screened by title/abstract before full-text
articles were retrieved for eligibility evaluation. Remaining articles
were then subject to a citation search before a final hand-search of
all reference lists.
Identification of eligible studies
Papers were deemed eligible if they included any form of in-trial
guideline focused on PRO assessment during clinical trials. We
defined the term ‘in-trial’ as relating to recruitment, data collection
and data inputting activity, occurring from the first participant
recruitment, through to inputting the final participant’s data. The
reviewers used the Oxford English Dictionary definition of the
word ‘guideline’ during eligibility screening; ‘‘a general rule,
principle, or piece of advice’’.[17] Non-English papers were
excluded. There were no other restrictions. All citations were
downloaded into EndnoteH software version 14, and duplicates
deleted. DK screened all articles by title/abstract to determine
their eligibility and AG reviewed a random sample of 10% in
order to evaluate the reliability of the selection process. Agreement
was high (Kappa= 0.903) and any discrepancies were resolved
through discussion. Full text articles were retrieved following first
round exclusions and were also subject to two independent
eligibility reviews (DK 100%, AG 10%), this time with perfect
agreement.
Data extraction
Data extraction occurred following the final selection of
included articles.
DK and CL independently searched each paper to identify all
sentences that provided any type of ‘guideline statement’ (which
we defined as ‘an expression in words of a general rule, principle,
or piece of advice’) regarding PRO measurement (in-trial or
otherwise). A consensus meeting was then held, to resolve any
disagreements and finalise the selection. Each sentence, repre-
senting one ‘guideline statement’, was then extracted, as a text
excerpt, into a mixed-method data analysis software package
(Dedoose  2011 SCRC) and tagged with its source data (Article
title, Journal, Year of publication).
Data analysis
DK and CL undertook a qualitative content analysis[18] of the
excerpts extracted from the included papers. All text excerpts were
categorised according to an a priori coding frame, which was
developed using a concept-driven strategy (i.e. codes were assigned
based on the authors’ prior knowledge of the literature and the
study research questions). DK and CL piloted the coding
framework, each independently applying the first draft to a
random selection of the included papers[6,7,19] (n = 3 (17%)).
Following the pilot, a meeting was held to discuss issues requiring
clarification and to reach consensus regarding the data-driven
changes that would improve the validity of the framework. Three
of the co-authors (MC, HD and JI), who possess expertise in PRO
design, implementation, reporting and ethics, checked and
approved the face validity of the final coding frame. The definitive
coding frame is presented in Figure 1. During the main analysis,
DK and CL independently categorised each guideline statement
according to the phase of trial activity to which it pertained, using
a major dimension within the coding frame. These major
dimensions were as follows; ‘Pre-Trial’, which included all content
relating to the trial inception (including training logistics), up to the
start of recruitment; ‘In-Trial’, denoting content directly related to
the act of trial recruitment, data collection and inputting; ‘Post-
Trial’, including activity taking place following data collection, for
example, data analysis/reporting; ‘Future Research’, representing
statements addressing the future direction of PRO research
activity; and ‘Other’, used to identify guideline statements not
captured in the main coding categories. Each individual guideline
was also sub-categorised, as appropriate, in order to further
identify its role within a given area.
Throughout both the pilot and the main analysis phase, the
reviewers met frequently to determine coding reliability for each
paper and to seek consensus regarding coding disagreements. The
reliability of coding application was determined using Cohen’s
PRO ’In-Trial’ Guidance: A Systematic Review
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kappa statistic.[20] Specifically, pooled kappa was employed, as it
is the preferred method of calculating inter-rater agreement across
a large number of coding items.[21] Face validity of the coding
frame was further evaluated by determining the proportion of
codes applied to the residuals (i.e., the ‘Other’ major- and sub-
categories). A high level of residual coding may indicate that the
main categories of the coding frame do not adequately describe
the concept under study.[18] Whilst there are no firm guidelines
regarding the desirable level of residual coding, we theorised that a
figure of less than 5% would support the validity of our coding
frame.
A protocol was not published or registered for this study.
However, all reviewers followed a protocol detailing a priori
determined search strategies, data extraction and data analysis
methods.
Results
Included studies
The search strategy yielded 1273 citations from MEDLINE,
EMBASE, AMED and CINHAL+, 89 citations were returned
using other sources (PROQUEST, professional bodies, Google,
expert communication) (PRISMA[22] flow diagram, Figure 2). In
total, 41 full text articles were retrieved for review. 25 articles were
excluded at this stage, as they contained no in-trial guideline
statements. An additional 2 papers were included following the
reference list and citation searches. A final total of 18 relevant
articles were included in the analysis.
Study characteristics
The characteristics of the 18 included papers are summarised in
Table 1. The majority of papers were concerned with the
incorporation of PRO/HRQL measures into cancer trial
design.[5,6,10,23–28] Several considered PRO issues relating to
pharmaceutical prescribing/labelling.[1,7,29–32] Two papers
presented generalised guidance on using PRO/HRQL measures
in clinical trials.[33,34] Finally, one paper presented recommen-
dations for PRO/HRQL assessment in allergy-related clinical
trials.[19] The included articles were drawn from 16 different
sources and the mean number of excerpts extracted from each
paper was 58 (range 16–127).
Data synthesis
Over 1,110 guideline statements were extracted and coded
following review of the 18 papers. The coding frame demonstrated
reliability, with pooled kappa ranging from 0.86 to 0.97 across
articles, and face validity, with overall residual coding at 1.2%. A
summary of the final coding breakdown is presented in Table 2.
Major coding categories
‘In-trial’ guidance, whilst present in all papers, did not represent
the major focus of any, accounting for 9.2% of guideline content
across the articles reviewed. ‘Pre-trial’ guidelines were predomi-
nant throughout (72.2%), again present in all papers. ‘Post-trial’
guidance was the next most prevalent category (15.8%), presented
across 13 articles.[1,5,7,10,19,23,24,28–33] Statements pertaining
to ‘future research’ represented 1.8% of guidelines (9 pa-
pers)[10,19,23,24,26–28,30,31] and the major category ‘Other’
was attributed to 1% of content (8 papers).[7,10,24,26,27,29–31]
Sub-categories
In-trial. There were no guideline statements addressing the
management of concerning PRO data, or related questions
Figure 1. Definitive coding frame. Major categories in bold.
doi:10.1371/journal.pone.0060684.g001
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Figure 2. PRISMA flow diagram of study selection process.
doi:10.1371/journal.pone.0060684.g002
Table 1. Study characteristics.
Included Studies Year of Publication Source Excerpts Extracted
Baiardini et al [19] 2010 Allergy 46
Basch et al [10] 2011 Value in Health 120
Calvert & Freemantle [1] 2004 Journal of Clinical Pharmacy and Therapeutics 74
Chassanay et al [29] 2002 Drug Information Journal 127
FDA [30] 2006 Health and Quality of Life Outcomes 86
FDA [7] 2009 FDA Website 116
Fayers [5] 1995 Quality of Life Research 18
Fayers et al [6] 1997 European Journal of cancer 62
Fletcher [23] 1995 British Journal of Clinical Pharmacology 48
Fletcher et al [24] 1992 BMJ 34
Hopwood et al [25] 1997 European Journal of cancer 25
Kiebert et al [26] 1998 Statistics in Medicine 16
Leidy et al [31] 1999 Value in Health 89
Luo & Cappelleri [33] 2008 Clinical Research and Regulatory Affairs 63
Moinpour et al [27] 1989 Journal of the National Cancer Institute 57
Movsas [28] 2003 Seminars in Radiation Oncology 39
Poulter [34] 1997 Good Clinical Practice Journal 19
Revicki et al [32] 2000 Quality of Life Research 80
doi:10.1371/journal.pone.0060684.t001
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including how additional information recorded on the back of
questionnaires should be handled and who should have routine
access to PRO data in the first instance. The majority of in-trial
guidelines (61.2%) tackled notions surrounding quality control,
compliance and the correct use of PROs.[1,5–7,10,19,24–
31,33,34] Authors highlighted the importance of minimising
missing items during data collection.[6,34] A number of papers
presented guidance aimed at improving compliance within a trial
in order to maximise data quality: examples included the proposed
education of local site staff, training of patients and use of real-time
adherence monitoring [1,5,6,10,24,25,27–29,34]. Other guide-
lines were concerned with piloting[27] and standardisation[28,31]
of data collection. Examples of suggested methods of standardisa-
tion included the following:
N A named individual, concerned with quality control, serving as
a PRO data collection contact at each research site within a
trial.[1,6,10]
N The use of standard scripts in interview- or telephone-based
questionnaires.[31]
N Ensuring that patients complete questionnaires at the same
pre-specified time point, usually selected so as to avoid the
undue influence of a preceding event.[31,33]
Where a trial participant is unable to complete their PRO
questionnaire, a proxy (commonly a partner or close relative) may
be asked to complete the form on their behalf. Discussion
surrounding the role of proxies represented 16.5% of in-trial
guidelines.[1,5,6,23,29,31,32] Authors mainly highlighted the
situations in which proxy assessment was justified.[1,5,6,29,31,32]
The use of a proxy was generally promoted as a last resort
[1,6,29], however it was acknowledged that proxy data was better
than no data at all.[5,29] The ideal identity of the proxy was
discussed by two authors, who concluded that, if possible, the same
person should be used throughout the trial[29] and they should be
close enough to the patient to provide valid data.[32] Guidelines
for the reporting of data collection represented 9.7% of in-trial
content[5,6,10,26,29,33] and were primarily concerned with the
need to document reasons for non-compliance[5,6,10,33] and the
need to report whether or not a proxy was used[6,29]. A small
number of in-trial guideline statements (7.8%) focused on patient
information, endorsing the use of a supplementary leaflet for
patients to take home[6], and highlighting the importance of the
investigator in ensuring the patient fully understands the role of
PRO measurement.[34] Two papers by the same author[5,6]
presented guidelines suggesting that PRO data should not be used
to influence management during a trial and one paper suggested
that trial participants ought to be informed when data would be
used for the benefit of future patients only.[10]
Table 2. Coding summary.
Coding Categories Example Excerpts
‘IN-TRIAL’ GUIDELINES (9.2%)
Quality control, compliance & correct use of OM (61.2%) ‘‘In order to maximize compliance when administering the questionnaire investigators
should… check the questionnaire for completeness at the time of visit and prompt
patients to try and complete any missing items.’’ [1]
Help/proxy assessments (16.5%) ‘‘Interviewers and proxies should be consistent during the trial.’’ [29]
Reporting of data collection/scoring (9.7%) ‘‘The reasons for missing data should be recorded at the time of occurrence and later
considered to lend insight into the potential patterns for why data are missing.’’ [33]
Participant information provision & understanding (7.8%) ‘‘The patient must fully understand the purpose of the QOL assessments.’’ [34]
Should PRO data inform management (4.8%) ‘‘Not only, therefore, should the information… not be used to influence treatment, but
the patient should be informed clearly that their replies are confidential…’’ [5]
‘PRE-TRIAL’ GUIDELINES (9.2%)
OM evaluation, OM selection, study design & procedure (87%) ‘‘Protocols should include clear justification for the assessment of HRQL, provide details
of the instrument and its properties, specify timings of assessments and emphasize the
need to maximize compliance.’’ [1]
OM development, validation, modification (12.8%) ‘‘A PROs tool can only be used in a language that differs from the original after
translation and back-translation, and a cross-cultural validation is performed.’’ [19]
Other (0.2%) ‘‘Requests for FDA input should be addressed to the review division responsible for the
medical product…’’ [7]
‘POST-TRIAL’ GUIDELINES (15.8%)
Data analysis, reporting, presentation (67.7%) ‘‘In settings where there is a large proportion of missing data due to toxicity, morbidity
or mortality, sensitivity analysis should be performed to address the possibility that the
missing data are non-ignorable or not missing at random.’’ [32]
Data interpretation, labeling & promotional claims (33.3%) ‘‘We suggest that, in general, two well-designed randomized clinical trials with
unequivocal results should provide sufficient evidence of an HRQL effect to substantiate
a claim in a given population.’’ [31]
‘FUTURE RESEARCH’ (1.8%) ‘‘A need exists to standardise the terminology used in studies and to define a minimum
set of concepts and dimensions of quality of life in order to justify a claim to have
measured quality of life.’’ [23]
‘OTHER’ (1%) ‘‘We encourage instrument developers to make their instruments and related
development history available and accessible publicly.’’ [7]
Major coding categories in bold. Abbreviations - OM: Outcome measure, QOL: Quality of Life, HRQL: Health-Related Quality of Life, PRO: Patient-Reported Outcome,
FDA: Food & Drug Administration.
doi:10.1371/journal.pone.0060684.t002
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Pre-trial. The majority of pre-trial guidelines (87%) were
focused on study design, procedural issues (including training
logistics) and the evaluation/selection of appropriate PRO
measures.[1,5–7,10,19,23–34] Others (12.8%) were concerned
with questionnaire development and validation, or with issues
arising from questionnaire modification.[1,7,10,19,23,24,28–33]
Post-trial. Most post-trial guidelines (66.7%) concentrated on
data analysis, reporting and presentation is-
sues.[1,5,7,10,19,23,24,28–33] The remaining guidance in this
area (33.3%) surrounded the interpretation of PRO data and
related labeling claims.[5,7,19,23,24,28–33]
Discussion
The purpose of this review was to investigate whether anecdotal
claims (subsequently confirmed by data under review), highlight-
ing a lack of in-trial PRO guidance, reflect a deficiency in the
published literature in this area. Our main findings suggest there a
minimal guidelines in publication focused on in-trial PRO activity
and there are a complete lack of guidelines addressing the
management of concerning PRO data.
Of the small number of in-trial guidelines that are in circulation,
the majority appear to deal with the procedural issues associated
with the prevention of missing data. This focus may be
understandable given the detrimental effect missing data may
have on a trial. Trial reports indicate that PRO questionnaires are
commonly returned with incomplete entries and some may not be
returned at all.[7] This data may not be missing at random and it
represents a serious potential bias when present.[10] Therefore, it
is encouraging there is some consensus in the guidelines reviewed.
To reduce missing PRO data, authors recommended that:
N The investigator/research nurse should: (1) motivate the
patients to complete all questionnaires in-full by ensuring they
understand the purpose and importance of the PRO
assessment within the trial, (2) check questionnaires for
completeness and prompt patients to fill in any missing items,
(3) show appreciation for the efforts of the patient in
completing the questionnaire.[1,5,6,25,27–29,33,34]
N PRO data is best collected in clinic, in an environment that is
private and free from distraction.[1,24,29,34]
N A centrally managed PRO data monitoring system should be
in place, coordinated at each site by a named individual,
tasked with; evaluating compliance across trial locations,
issuing data collection reminders to patients where needed
and chasing-up missing items.[1,6,10,25,27,28]
The guidance surrounding missing data is therefore compre-
hensive. In contrast, no guidelines appear to adequately address
aspects surrounding the management of concerning PRO data.
This may be a problem given this issue has been identified as key
by those involved in PRO data collection, as it can result in dual-
role tension and may risk the potential introduction of bias into a
trial.
A PRO questionnaire may be the only outcome within a trial
capable of identifying ‘tolerable’ symptoms such as participant
anxiety or depression; and the research nurse checking the form
may be the only individual to whom participants have disclosed
how they feel. Understandably, nurses may feel it is their duty to
intervene when faced with PRO data that raises concern for the
participant. A problem arises if the intervention is non-medicinal;
for example, words of comfort, or advice to visit one’s general
practitioner, or if the advice results in the participant self-
medicating. Direct medicinal interventions are far more easily
controlled-for during data analysis. Non-medicinal or self-directed
interventions, that are selectively delivered in response to
concerning PRO data, may influence patient well-being but
remain unrecorded in the trial documentation: this may represent
a hitherto unforeseen source of bias.
Research nurses have reported experiencing dual-role tension
when handling PRO data. Dual-role tension arises when an
individual’s values and responsibilities as a researcher conflict with
those associated with being a clinical practitioner. Assuming
ethical norms have been followed and participant ‘risk and
burden’ does not outweigh the potential benefit of trial participa-
tion [35], the nurse researcher may justifiably choose not to
intervene when concerning PRO data is disclosed, in order to
protect trial integrity. This decision may be driven by consequen-
tialist values, geared toward achieving the greatest benefit at the
lowest cost, and reasoning that the benefits of producing unbiased
trial results outweigh the personal costs experienced by the ‘few’
participants who continue to (tolerably) suffer. Conversely, nurse
practitioners are obliged to make the care of their patients their first
concern, as outlined in the Nursing and Midwifery Council code
of conduct[36], which compels them to take steps to address any
evident suffering. This conflict between the two professional duties
has been recognized elsewhere[37–39]. However, what sets PRO
data collection apart from the management of other trial outcomes
is the current lack of published, and trial-based, guidance in this
area. In our experience, the trial protocol often contains clear
guidelines surrounding the levels at which some clinical outcomes,
blood pressure for example, need to reach before the data collector
should become concerned.[9] There is usually also a clear system
in place to manage participants whose clinical measurements
exceed agreed limits. Equivalent guidance is not always provided
for PROs. Thus, the researcher collecting/inputting PRO data
may be left to determine independently, on a case-by-case basis,
whether PRO results signal a risk to the participant that outweighs
the benefit of trial involvement. We believe this situation places
unreasonable demands upon the researcher and promotes
inconsistency, as there is unlikely to be uniformity in decision-
making across trial sites; this may adversely affect data quality.
Our findings highlight the need to develop and publish specific
guidelines that clearly outline how concerning PRO data should
be handled, as there are none currently in circulation. PRO in-
trial guidelines should be brought in line with those covering
traditional clinical outcomes and should define the conditions
under which the researcher may take remedial action, and the
form this intervention might take.
Limitations
Non-English language papers were excluded from the review,
which potentially lessens the generalisability of the results
presented. However, this decision was taken as a key element of
qualitative content analysis involved determining the implied or
latent meaning of the material.[18] We questioned the validity of
such analysis using material translated from the original language
by a third party, as some latent meaning may be lost during the
translation process. Our search strategy dictated that we carefully
reviewed papers for their guideline content only if their title/
abstract gave an indication that some aspect of in-trial activity
might be discussed. It is possible that papers providing ‘in-trial’
guidance exist, which make no reference to in-trial activity in their
title or abstract.
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Conclusions
In-trial guidelines aimed at PRO recruitment, data collection
and data inputting within clinical trials are lacking. No guidance
appears to exist for researchers involved with the handling of
concerning PRO data. This is a worry as this activity may be
associated with considerable personal and professional anxiety and
may risk the introduction of bias when the ethical tension
generated, is resolved in favour of responding to the needs of the
patient over the expectations of the trial. Further research is
needed to produce guidelines aimed at supporting researchers so
they can deal effectively with dual-role tensions, manage PRO
data appropriately and facilitate unbiased data collection.
Supporting Information
Appendix S1 Search strategies.
(DOCX)
Box S1 Definition of terms.
(DOCX)
Acknowledgments
We would like to thank the National School of Primary Care Research and
the MRC Midland Hub for Trials Methodology Research for assistance
with the development of this review.
Author Contributions
Conceived and designed the experiments: DK MC HD JI. Performed the
experiments: DK AG. Analyzed the data: DK CL. Wrote the paper: DK.
Critical revision of manuscript: DK MC HD JI CL AG. Obtained funding:
DK MC HD JI.
References
1. Calvert M, Freemantle N (2004) Use of health-related quality of life in
prescribing research. Part 2: methodological considerations for the assessment of
health-related quality of life in clinical trials. Journal of Clinical Pharmacy and
Therapeutics 29: 85-94.
2. Lemieuz J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V (2011) Quality-
of-life measurement in randomized clinical trials in breast cancer: An updated
systematic review (2001–2009). Journal of the National Cancer Institute 103:
178-231.
3. Sajid MS, Tonsi A, Baig MK (2008) Health-related quality of life measurement.
International Journal of Health Care 21: 365-373.
4. Calvert MJ, Freemantle N (2003) Use of health-related quality of life in
prescribing research. Part 1: why evaluate health-related quality of life? Journal
of Clinical Pharmacy and Therapeutics 28: 513-521.
5. Fayers P (1995) MRC quality of life studies using a daily diary card--practical
lessons learned from cancer trials. [Review] [42 refs]. Quality of Life Research 4:
343-352.
6. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, et al. (1997) Quality
of life assessment in clinical trials--guidelines and a checklist for protocol writers:
the U.K. Medical Research Council experience. MRC Cancer Trials Office.
European Journal of Cancer 33: 20-28.
7. FDA (2009) Guidance for Industry: Patient-Reported Outcome Measures: Use
in Medical Product Development to Support Labeling Claims. US Food & Drug
Administration Website. Available: http://www.fda.gov/downloads/Drugs/
Guidances/UCM193282.pdf. Accessed 1st March, 2012.
8. Chan A, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, et al. (2013) SPIRIT
2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ
346: 1-42.
9. Kyte D, Draper H, Ives J, Keely T, Calvert M(under review) Inconsistencies in
Health-Related Quality of Life (HRQL) data-collection in clinical trials – a
potential source of bias? Interviews with research nurses and trialists.
10. Basch EM, Abernethy A, Mullins CD, Tiglao MR, Tunis SR (2011)
Development of a guidance for including patient-reported outcomes (PROs) in
post-approval clinical trials of oncology drugs for comparative effectiveness
research (CER). Value in Health 14(3): A10.
11. Calvert M, Blazeby J, Altman DG, Revicki D, Moher D, et al. (2013) Reporting
of Patient Reported Outcomes in Randomised Trials: the CONSORT PRO
Extension. JAMA, 309(8):814-22. doi: 10.1001/jama.2013.879.
12. FDA (2012) US Food & Drug Administration Website. Available: http://www.
fda.gov/. Accessed 1st March, 2012.
13. EMA (2012) European Medicines Agency website. Available: http://www.ema.
europa.eu/ema/. Accessed 1st March, 2012.
14. GMC (2012) General Medical Council website. Available: http://www.gmc-uk.
org/. Accessed 1st March, 2012.
15. MRC (2012) Medical Research Council website. Available: http://www.mrc.ac.
uk/index.htm. Accessed 1st March, 2012.
16. RCN (2012) Royal College of Nursing website. Available: http://www.rcn.org.
uk/. Accessed 1st March, 2012.
17. Oxford University Press (2012) Oxford Dictionairies Online. Oxford University
Press, UK. Available: http://oxforddictionaries.com. Accessed 1st March, 2012.
18. Schreier M (2012) Qualitative content analysis in practice. London: SAGE
Publications Ltd.
19. Baiardini I, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, et al. (2010)
Recommendations for assessing patient-reported outcomes and health-related
quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper.
Allergy 65: 290-295.
20. Cohen J (1960) A coefficient of agreement for nominal scales. Educational and
Psychological Measurement 20: 37-46.
21. De Vries H, Elliott MN, Kanouse DE, Teleki SS (2008) Using Pooled Kappa to
Summarize Interrater Agreement across Many Items. Field Methods 20: 272-
282.
22. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred Reporting Items
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS
Medicine 6: e1000097.
23. Fletcher A (1995) Quality-of-life measurements in the evaluation of treatment:
proposed guidelines. British Journal of Clinical Pharmacology 39: 217-222.
24. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, et al. (1992) Quality
of life measures in healthcare. II: Design, analysis, and interpretation. BMJ 305:
1145-1148.
25. Hopwood P, Harvey A, Davies J, Stephens RJ, Girling DJ, et al. (1998) Survey of
the Administration of quality of life (QL) questionnaires in three multicentre
randomised trials in cancer. The Medical Research Council Lung Cancer
Working Party the CHART Steering Committee. European Journal of Cancer
34: 49-57.
26. Kiebert GM, Curran D, Aaronson NK (1998) Quality of life as an endpoint in
EORTC clinical trials. Statistics in Medicine 17: 561-569.
27. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, et al. (1989)
Quality of life end points in cancer clinical trials: review and recommendations.
Journal of the National Cancer Institute 81: 485-495.
28. Movsas B (2003) Quality of life in oncology trials: a clinical guide. Seminars in
Radiation Oncology 13: 235-247.
29. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N (2002) Patient-
reported outcomes: The example of health-related quality of life - A European
guidance document for the improved integration of health-related quality of life
assessment in the drug regulatory process. Drug Information Journal 36: 209-
238.
30. FDA (2006) Guidance for industry: patient-reported outcome measures: use in
medical product development to support labeling claims: draft guidance. Health
& Quality of Life Outcomes 4: 79.
31. Leidy NK, Revicki DA, Geneste B (1999) Recommendations for Evaluating the
Validity of Quality of Life Claims for Labeling and Promotion. Value in Health
2: 113-127.
32. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, et al. (2000)
Recommendations on health-related quality of life research to support labeling
and promotional claims in the United States. Quality of Life Research 9: 887-
900.
33. Luo X, Cappelleri JC (2008) A practical guide on incorporating and evaluating
patient-reported outcomes in clinical trials. Clinical Research and Regulatory
Affairs 25: 197-211.
34. Poulter K (1997) The administration of quality of life questionnaries within
clinical trials. Good Clinical Practice Journal 4: 22-25.
35. WMA (2008) World Medical Association Delaration of Helsinki: Ethical
pricinples of medical research involving human subjects. World Medial
Association: 1-5 p.
36. NMC (2008) The code: Standards of conduct, performance and ethics for nurses
and midwives. The Nursing & Midwifery Council website. Available: http://
www.nmc-uk.org/Documents/Standards/The-code-A4-20100406.pdf. Ac-
cessed 1st March, 2013.
37. Edwards M, Chalmers K (2002) Double agency in clinical research. Canadian
Journal of Nursing Research 34: 131-142.
38. Houghton CE, Casey D, Shaw D, Murphy K (2010) Ethical challenges in
qualitative research: examples from practice. Nurse Researcher 18: 15-25.
39. Holloway I, Wheeler S (1995) Ethical issues in qualitative nursing research.
Nursing Ethics 2: 223-232.
PRO ’In-Trial’ Guidance: A Systematic Review
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e60684
